ASCO: New drug effective for metastatic prostate cancer

This article originally appeared here.
ASCO: New Drug Slows Metastatic Prostate Cancer
ASCO: New Drug Slows Metastatic Prostate Cancer

(HealthDay News) -- Enzalutamide, an oral androgen-receptor inhibitor, is superior to placebo for the treatment of metastatic prostate cancer before chemotherapy, according a study published online June 1 in the New England Journal of Medicine. This research was published to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 30 to June 3 in Chicago.

Tomasz M. Beer, M.D., of the Oregon Health and Science University in Portland, and colleagues randomly assigned 1,717 patients with metastatic prostate cancer to receive either enzalutamide or placebo.

The researchers found that, at 12 months, radiographic progression-free survival was significantly higher in men receiving enzalutamide than in those receiving placebo (65 versus 14 percent; hazard ratio [HR], 0.19). At the data-cutoff date, more patients in the enzalutamide group than in the placebo group were alive (72 versus 63 percent; HR, 0.71). Increased time to initiation of cytotoxic chemotherapy also was observed in the enzalutamide group (HR, 0.35).

"Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including study funders Medivation and Astellas Pharma, the manufacturers of enzalutamide.

Full Text
More Information

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs